Cara Therapeutics, Inc. (0HTC.L)
USD 5.33
(-0.22%)
USD 5.33
(-0.22%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 142.46 Million USD | 11.38% |
| 2022 | 122.13 Million USD | 8.94% |
| 2021 | 112.11 Million USD | -13.56% |
| 2020 | 129.69 Million USD | -1.42% |
| 2019 | 131.56 Million USD | 44.81% |
| 2018 | 90.85 Million USD | 50.43% |
| 2017 | 60.39 Million USD | 3.27% |
| 2016 | 58.48 Million USD | 101.74% |
| 2015 | 28.99 Million USD | 36.43% |
| 2014 | 21.24 Million USD | 74.16% |
| 2013 | 12.2 Million USD | 64.3% |
| 2012 | 7.42 Million USD | -22.37% |
| 2011 | 9.56 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 17.12 Million USD | -36.33% |
| 2024 Q1 | 28.73 Million USD | -17.71% |
| 2023 Q3 | 33.76 Million USD | -10.81% |
| 2023 Q1 | 31.22 Million USD | -3.74% |
| 2023 FY | 136.03 Million USD | 11.38% |
| 2023 Q2 | 37.85 Million USD | 21.23% |
| 2023 Q4 | 34.92 Million USD | 3.43% |
| 2022 FY | 122.13 Million USD | 8.94% |
| 2022 Q4 | 32.43 Million USD | 2.64% |
| 2022 Q3 | 31.6 Million USD | 15.02% |
| 2022 Q2 | 27.47 Million USD | -10.27% |
| 2022 Q1 | 30.62 Million USD | -10.84% |
| 2021 Q4 | 34.34 Million USD | 60.51% |
| 2021 Q2 | 30.87 Million USD | 21.1% |
| 2021 FY | 112.11 Million USD | -13.56% |
| 2021 Q1 | 25.49 Million USD | -24.57% |
| 2021 Q3 | 21.39 Million USD | -30.7% |
| 2020 Q4 | 33.79 Million USD | 28.58% |
| 2020 Q3 | 26.28 Million USD | -16.6% |
| 2020 Q2 | 31.51 Million USD | -17.26% |
| 2020 Q1 | 38.09 Million USD | 10.48% |
| 2020 FY | 129.69 Million USD | -1.42% |
| 2019 Q1 | 27.51 Million USD | 0.02% |
| 2019 FY | 131.56 Million USD | 44.81% |
| 2019 Q2 | 29.35 Million USD | 6.67% |
| 2019 Q3 | 40.21 Million USD | 37.03% |
| 2019 Q4 | 34.48 Million USD | -14.26% |
| 2018 FY | 90.85 Million USD | 50.43% |
| 2018 Q4 | 27.51 Million USD | 7.76% |
| 2018 Q3 | 25.53 Million USD | 23.41% |
| 2018 Q2 | 20.68 Million USD | 20.81% |
| 2018 Q1 | 17.12 Million USD | 17.52% |
| 2017 Q3 | 12.95 Million USD | 34.5% |
| 2017 Q2 | 9.63 Million USD | -58.54% |
| 2017 Q4 | 14.57 Million USD | 12.47% |
| 2017 Q1 | 23.23 Million USD | 4.13% |
| 2017 FY | 60.39 Million USD | 3.27% |
| 2016 Q2 | 13.4 Million USD | 21.94% |
| 2016 FY | 58.48 Million USD | 101.74% |
| 2016 Q4 | 22.31 Million USD | 89.54% |
| 2016 Q3 | 11.77 Million USD | -12.17% |
| 2016 Q1 | 10.99 Million USD | 12.99% |
| 2015 Q3 | 7.44 Million USD | 12.76% |
| 2015 Q2 | 6.6 Million USD | 26.87% |
| 2015 Q1 | 5.2 Million USD | -0.82% |
| 2015 FY | 28.99 Million USD | 36.43% |
| 2015 Q4 | 9.72 Million USD | 30.61% |
| 2014 Q1 | 3.59 Million USD | 16.93% |
| 2014 Q3 | 7.72 Million USD | 65.41% |
| 2014 Q4 | 5.25 Million USD | -32.07% |
| 2014 FY | 21.24 Million USD | 74.16% |
| 2014 Q2 | 4.67 Million USD | 29.81% |
| 2013 Q2 | 3.05 Million USD | 102.25% |
| 2013 Q4 | 3.07 Million USD | -32.49% |
| 2013 Q1 | 1.51 Million USD | -14.64% |
| 2013 FY | 12.2 Million USD | 64.3% |
| 2013 Q3 | 4.55 Million USD | 49.28% |
| 2012 FY | 7.42 Million USD | -22.37% |
| 2012 Q4 | 1.76 Million USD | -41.77% |
| 2012 Q3 | 3.03 Million USD | 0.0% |
| 2011 FY | 9.56 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | 50.028% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -193.726% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -1073.404% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 65.151% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 48.325% |
| Imunon, Inc. | 21.03 Million USD | -577.414% |
| Dynavax Technologies Corporation | 219.14 Million USD | 34.991% |
| Editas Medicine, Inc. | 247.3 Million USD | 42.394% |
| FibroGen, Inc. | 398.11 Million USD | 64.215% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 68.411% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -263.862% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 91.077% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 89.531% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 73.07% |
| Verastem, Inc. | 92.08 Million USD | -54.71% |
| Zoetis Inc. | 2.76 Billion USD | 94.848% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 97.016% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 37.702% |
| Homology Medicines, Inc. | 9.87 Million USD | -1342.663% |
| Nektar Therapeutics | 190.9 Million USD | 25.374% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -41.294% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -218.945% |
| Perrigo Company plc | 1.52 Billion USD | 90.68% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 47.604% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.649% |
| Illumina, Inc. | 3.81 Billion USD | 96.264% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 98.611% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 93.061% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -18.073% |
| Waters Corporation | 943.51 Million USD | 84.901% |
| Biogen Inc. | 5.2 Billion USD | 97.263% |
| Evolus, Inc. | 189.75 Million USD | 24.924% |
| Adicet Bio, Inc. | 152.03 Million USD | 6.298% |
| bluebird bio, Inc. | 240.23 Million USD | 40.698% |
| Geron Corporation | 70.44 Million USD | -102.244% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 92.086% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 66.687% |
| Myriad Genetics, Inc. | 600.1 Million USD | 76.26% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 74.171% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 86.923% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -924.203% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 91.842% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 94.94% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 93.264% |
| OPKO Health, Inc. | 574.68 Million USD | 75.21% |
| Exelixis, Inc. | 1.58 Billion USD | 91.022% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 61.352% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -155.512% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 70.093% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 81.726% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 52.404% |
| Blueprint Medicines Corporation | 722.86 Million USD | 80.292% |
| Insmed Incorporated | 949.26 Million USD | 84.992% |
| TG Therapeutics, Inc. | 198.47 Million USD | 28.221% |
| Incyte Corporation | 1.19 Billion USD | 88.033% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 86.354% |